Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00094497 · OUTCOME

Best Overall Response Rate

Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT) · Source last updated 2016-09-21

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
participants
Interval / dispersion
Not reported
Time frame
every 8 weeks up to 5 years

What was measured

RECIST 1.0 was used to evaluate response

Groups in this outcome

EDP-M

etopodide, doxorubicin, cisplatin and mitotane Etoposide Doxorubicin Cisplatin Mitotane participants who progressed during first line therapy, were eligible to the alternative treatment (Sz-M)

Sz-M

streptozotocin and mitotane Streptozotocin Mitotane participants who progressed during first line therapy, were eligible to the alternative treatment (EDP-M)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
EDP-M151
Sz-M153

Reported measurements

complete response
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
EDP-M2Not reportedNot reportedNot reportedNot reported
Sz-M1Not reportedNot reportedNot reportedNot reported
disease-free by time of surgery
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
EDP-M4Not reportedNot reportedNot reportedNot reported
Sz-M2Not reportedNot reportedNot reportedNot reported
partial response
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
EDP-M29Not reportedNot reportedNot reportedNot reported
Sz-M11Not reportedNot reportedNot reportedNot reported
stable disease
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
EDP-M53Not reportedNot reportedNot reportedNot reported
Sz-M34Not reportedNot reportedNot reportedNot reported
progressive disease
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
EDP-M43Not reportedNot reportedNot reportedNot reported
Sz-M88Not reportedNot reportedNot reportedNot reported
did not receive treatment
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
EDP-M3Not reportedNot reportedNot reportedNot reported
Sz-M4Not reportedNot reportedNot reportedNot reported
could not be evaluated
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
EDP-M17Not reportedNot reportedNot reportedNot reported
Sz-M13Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        2
      2. group Id
        OG001
        value
        1
    title
    complete response
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        4
      2. group Id
        OG001
        value
        2
    title
    disease-free by time of surgery
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        29
      2. group Id
        OG001
        value
        11
    title
    partial response
  4. categories
    1. measurements
      1. group Id
        OG000
        value
        53
      2. group Id
        OG001
        value
        34
    title
    stable disease
  5. categories
    1. measurements
      1. group Id
        OG000
        value
        43
      2. group Id
        OG001
        value
        88
    title
    progressive disease
  6. categories
    1. measurements
      1. group Id
        OG000
        value
        3
      2. group Id
        OG001
        value
        4
    title
    did not receive treatment
  7. categories
    1. measurements
      1. group Id
        OG000
        value
        17
      2. group Id
        OG001
        value
        13
    title
    could not be evaluated
denoms
  1. counts
    1. group Id
      OG000
      value
      151
    2. group Id
      OG001
      value
      153
    units
    Participants
description
RECIST 1.0 was used to evaluate response
groups
  1. description
    etopodide, doxorubicin, cisplatin and mitotane Etoposide Doxorubicin Cisplatin Mitotane participants who progressed during first line therapy, were eligible to the alternative treatment (Sz-M)
    id
    OG000
    title
    EDP-M
  2. description
    streptozotocin and mitotane Streptozotocin Mitotane participants who progressed during first line therapy, were eligible to the alternative treatment (EDP-M)
    id
    OG001
    title
    Sz-M
param Type
NUMBER
reporting Status
POSTED
time Frame
every 8 weeks up to 5 years
title
Best Overall Response Rate
type
SECONDARY
unit Of Measure
participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice